TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Geoffrey OxnardM-J Ahn

Abstract

Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study (NCT02143466) was designed to assess the safety and tolerability of osimertinib in combination with other targeted therapies: selumetinib (MEK1/2 inhibitor), savolitinib (MET-TKI), or durvalumab [anti-programmed cell death ligand 1 (anti-PD-L1) monoclonal antibody]. Patients with advanced EGFR-mutant non-small-cell lung cancer and disease progression on a prior EGFR-TKI were enrolled and allocated to dose-escalating cohorts combining osimertinib 80 mg orally (p.o.) once a day with selumetinib (25-75 mg p.o. twice a day; continuous or intermittent), savolitinib (600-800 mg p.o. once a day), or durvalumab (3-10 mg/kg intravenous every 2 weeks). At data cut-off (28 February 2018), 77 patients were enrolled and received osimertinib plus selumetinib (n = 36), savolitinib (n = 18), or durvalumab (n = 23). Most common adverse events (any grade), occurring in ≥20% of patients across dose groups, were: selumetinib arm-diarrhea (75%), rash (58%), nausea (47%); savolitinib arm-nausea (67%), rash (56%), vomiting (50%); durvalumab arm-rash (48%), vomiting (43%), diarrhea (39%). Dose-limiting ...Continue Reading

References

Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tammie C YehEli Wallace
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J RielyVincent A Miller
May 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George N NaumovJohn V Heymach
May 19, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistJean-Charles Soria
Oct 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistRonald Natale
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick J Roberts, Thomas E Stinchcombe
Feb 7, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nan ChenLi Zhang
May 13, 2015·Seminars in Oncology·Ramy IbrahimAiman Shalabi
Oct 22, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chee Khoon LeeJames Chih-Hsin Yang
Nov 16, 2016·ESMO Open·Floriana MorgilloFortunato Ciardiello
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Oct 27, 2017·Nature Reviews. Cancer·Julia Rotow, Trever G Bivona
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Jun 7, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·A LisbergEdward B Garon
Feb 15, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James Chih-Hsin YangLeora Horn
Aug 15, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vanita NoronhaKumar Prabhash
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Jun 13, 2020·Expert Review of Anticancer Therapy·Giulia SartoriSara Pilotto
Jun 6, 2020·Future Oncology·Maria Virginia BluthgenGonzalo Recondo
Sep 6, 2020·Cancer·Alex FriedlaenderAlfredo Addeo
Sep 12, 2020·Cancer Immunology, Immunotherapy : CII·H AdderleyC R Lindsay
Aug 9, 2020·OncoTargets and Therapy·Sneha GullapalliGilberto Lopes
Jul 4, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Eiko IwasaRika Wakao
Jun 20, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J Piper-VallilloZofia Piotrowska
Jun 7, 2020·Drugs·Anthony Markham, Susan J Keam
Jul 2, 2020·OncoTargets and Therapy·Olivier BylickiChristos Chouaïd
Aug 7, 2020·Expert Review of Anticancer Therapy·D FranceschiniM Scorsetti
Oct 31, 2020·Current Opinion in Oncology·Lingyun YeFei Zhou
Oct 22, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ezra Y RosenGeoffrey R Oxnard
Jan 20, 2021·Nature Reviews. Cancer·Shogo KumagaiHiroyoshi Nishikawa
Jan 1, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhencong YeHui Luo
Feb 14, 2021·NPJ Precision Oncology·Maurício Fernando Silva Almeida RibeiroArtur Katz
Jan 7, 2021·Journal of Hematology & Oncology·Jing HanQiming Wang
Jan 21, 2021·International Journal of Molecular Sciences·Tohru OhmoriHironori Sagara
Jan 29, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Juan ZhouChunxia Su
Nov 18, 2020·International Journal of Molecular Sciences·Jorge Esteban-VillarrubiaJavier Molina-Cerrillo
Dec 11, 2020·The Cancer Journal·Alexander Gavralidis, Justin F Gainor
Jan 25, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Vered FuchsNir Peled
Feb 18, 2021·Expert Opinion on Pharmacotherapy·Luigi CerboneCarlo Genova
Jan 27, 2021·Critical Reviews in Oncology/hematology·Fatemeh MoosaviOmidreza Firuzi
Nov 25, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikJohanna Bendell
Dec 24, 2020·Clinical Pharmacokinetics·Olivia CampagneClinton F Stewart
Mar 28, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K RzeniewiczS Turajlic
Apr 6, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Rie FurukawaIsamu Okamoto
Apr 24, 2021·Respiratory Medicine and Research·K El Husseini, M Wislez
May 5, 2021·Expert Opinion on Therapeutic Targets·Matthew LeeBalazs Halmos
Apr 30, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Meng QiaoCaicun Zhou
May 27, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jessica Bauman, Hossein Borghaei

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.